{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:25:54Z","timestamp":1793330754797,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01768-1","type":"journal-article","created":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T20:13:29Z","timestamp":1765138409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timucin","family":"Cil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mingyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Krzakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Dikilitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali Nahit","family":"Sendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-1681","authenticated-orcid":false,"given":"Luhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"issue":"3","key":"1768_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1768_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","volume":"10","author":"A Casal-Mourino","year":"2021","unstructured":"Casal-Mourino A, Ruano-Ravina A, Lorenzo-Gonzalez M, Rodriguez-Martinez A, Giraldo-Osorio A, Varela-Lema L, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506\u201318.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"1768_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.21037\/tlcr.2019.08.05","volume":"8","author":"M Provencio","year":"2019","unstructured":"Provencio M, Carcereny E, Rodriguez-Abreu D, Lopez-Castro R, Guirado M, Camps C, et al. Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Transl Lung Cancer Res. 2019;8(4):461\u201375.","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"1768_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/thoraxjnl-2012-202297","volume":"68","author":"S Walters","year":"2013","unstructured":"Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004\u20132007. Thorax. 2013;68(6):551\u201364.","journal-title":"Thorax"},{"issue":"12","key":"1768_CR5","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.21.02528","volume":"40","author":"ME Daly","year":"2022","unstructured":"Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, et al. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 2022;40(12):1356\u201384.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1768_CR6","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon J, Soria JC, Peters S, ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637\u201342.","journal-title":"Ann Oncol"},{"issue":"2","key":"1768_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.annonc.2019.10.026","volume":"31","author":"K Park","year":"2020","unstructured":"Park K, Vansteenkiste J, Lee KH, Pentheroudakis G, Zhou C, Prabhash K, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Ann Oncol. 2020;31(2):191\u2013201.","journal-title":"Ann Oncol"},{"issue":"9","key":"1768_CR8","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052\u201362.","journal-title":"Cancer Immunol Res"},{"issue":"20","key":"1768_CR9","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"1768_CR10","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342\u201350.","journal-title":"N Engl J Med"},{"issue":"12","key":"1768_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301\u201311.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1768_CR12","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","volume":"20","author":"R Hui","year":"2019","unstructured":"Hui R, Ozguroglu M, Villegas A, Daniel D, Vicente D, Murakami S, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(12):1670\u201380.","journal-title":"Lancet Oncol"},{"issue":"13","key":"1768_CR13","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","volume":"28","author":"A Auperin","year":"2010","unstructured":"Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181\u201390.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1768_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/annonc\/mdn559","volume":"20","author":"D De Ruysscher","year":"2009","unstructured":"De Ruysscher D, Botterweck A, Dirx M, Pijls-Johannesma M, Wanders R, Hochstenbag M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol. 2009;20(1):98\u2013102.","journal-title":"Ann Oncol"},{"issue":"11","key":"1768_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.5306\/wjco.v11.i11.898","volume":"11","author":"X Mielgo-Rubio","year":"2020","unstructured":"Mielgo-Rubio X, Rojo F, Mezquita-Perez L, Casas F, Wals A, Juan M, et al. Deep diving in the PACIFIC: practical issues in stage III non-small cell lung cancer to avoid shipwreck. World J Clin Oncol. 2020;11(11):898\u2013917.","journal-title":"World J Clin Oncol"},{"issue":"12","key":"1768_CR16","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","volume":"17","author":"MC Garassino","year":"2022","unstructured":"Garassino MC, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N, et al. Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial. J Thorac Oncol. 2022;17(12):1415\u201327.","journal-title":"J Thorac Oncol"},{"key":"1768_CR17","unstructured":"Rami-Porta R. International Association for the Study of Lung Cancer. IASLC Staging Manual in Thoracic Oncology. 2016."},{"key":"1768_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0099-9","volume":"4","author":"M Yuan","year":"2019","unstructured":"Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1768_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611\u201325.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1768_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","volume":"16","author":"C Faivre-Finn","year":"2021","unstructured":"Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial. J Thorac Oncol. 2021;16(5):860\u20137.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1768_CR21","doi-asserted-by":"publisher","first-page":"e1822","DOI":"10.1002\/onco.13900","volume":"26","author":"X Chen","year":"2021","unstructured":"Chen X, Sheikh K, Nakajima E, Lin CT, Lee J, Hu C, et al. Radiation versus immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies. Oncologist. 2021;26(10):e1822\u201332.","journal-title":"Oncologist"},{"issue":"3","key":"1768_CR22","first-page":"100638","volume":"5","author":"JF Vansteenkiste","year":"2024","unstructured":"Vansteenkiste JF, Naidoo J, Faivre-Finn C, Ozguroglu M, Villegas A, Daniel D, et al. Symptomatic pneumonitis with durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC. JTO Clin Res Rep. 2024;5(3):100638.","journal-title":"JTO Clin Res Rep"},{"issue":"3","key":"1768_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2307\/2336502","volume":"70","author":"KKG Lan","year":"1983","unstructured":"Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70(3):659\u201363.","journal-title":"Biometrika"},{"issue":"4","key":"1768_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jtho.2017.12.011","volume":"13","author":"L Nygard","year":"2018","unstructured":"Nygard L, Vogelius IR, Fischer BM, Kjaer A, Langer SW, Aznar MC, et al. A competing risk model of first failure site after definitive chemoradiation therapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(4):559\u201367.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1768_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/jrr\/rrac057","volume":"64","author":"N Kishi","year":"2023","unstructured":"Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N, et al. Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer. J Radiat Res. 2023;64(1):142\u201353.","journal-title":"J Radiat Res"},{"issue":"10","key":"1768_CR26","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jtho.2020.04.028","volume":"15","author":"S Gao","year":"2020","unstructured":"Gao S, Li N, Wang S, Zhang F, Wei W, Li N, et al. Lung cancer in People\u2019s Republic of China. J Thorac Oncol. 2020;15(10):1567\u201376.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1768_CR27","first-page":"2","volume":"1","author":"S Zhang","year":"2021","unstructured":"Zhang S, Sun K, Zheng R, Zeng H, Wang S, Chen R, et al. Cancer incidence and mortality in China, 2015. J Natl Cancer Cent. 2021;1(1):2\u201311.","journal-title":"J Natl Cancer Cent"},{"issue":"2","key":"1768_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23(2):209\u201319.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1768_CR29","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.jtho.2022.07.021","volume":"17","author":"YL Wu","year":"2022","unstructured":"Wu YL, Zhou Q, Chen M, Pan Y, Jian O, Hu D, et al. Sugemalimab vs placebo after cCRT or sCRT in Pts with unresectable stage III NSCLC: final PFS analysis of a phase 3 study. J Thorac Oncol. 2022;17(9):S7\u20138.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1768_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","volume":"18","author":"N Girard","year":"2023","unstructured":"Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, et al. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol. 2023;18(2):181\u201393.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1768_CR31","doi-asserted-by":"publisher","first-page":"e247542","DOI":"10.1001\/jamanetworkopen.2024.7542","volume":"7","author":"MJ Mooradian","year":"2024","unstructured":"Mooradian MJ, Cai L, Wang A, Qiao Y, Chander P, Whitaker RM. Durvalumab after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer. JAMA Netw Open. 2024;7(4):e247542.","journal-title":"JAMA Netw Open"},{"issue":"Suppl 11","key":"1768_CR32","doi-asserted-by":"publisher","first-page":"S569","DOI":"10.1016\/j.jtho.2023.09.1067","volume":"18","author":"N Pringle","year":"2023","unstructured":"Pringle N, Fletcher JA, Morton C, Mullally WJ, Arneil M, O\u2019Byrne K, et al. EP08.02-03 real world experience of survival outcomes in consolidative durvalumab in unresectable stage III non-small cell lung cancer (NSCLC). J Thorac Oncol. 2023;18(Suppl 11):S569.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"1768_CR33","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1016\/j.jtho.2023.09.232","volume":"18","author":"P Wheatley-Price","year":"2023","unstructured":"Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, et al. MA16.06 Real-world survival with CRT\u2009+\u2009durvalumab for unresectable, stage III NSCLC in Canada: the RELEVANCE study. J Thorac Oncol. 2023;18(11):S159.","journal-title":"J Thorac Oncol"},{"issue":"Suppl 3","key":"1768_CR34","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1016\/j.ijrobp.2021.07.1242","volume":"111","author":"HP Hu","year":"2021","unstructured":"Hu HP, Walker C, Swaminath A. Real-world outcomes of chemoradiation and consolidative durvalumab in unresectable stage III non-small-cell lung cancer \u2014 a systematic review. Int J Radiat Oncol Biol Phys. 2021;111(Suppl 3):e438.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1768_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01436-2","volume":"16","author":"SM Liu","year":"2023","unstructured":"Liu SM, Zheng MM, Pan Y, Liu SY, Li Y, Wu YL. Emerging evidence and treatment paradigm of non-small cell lung cancer. J Hematol Oncol. 2023;16(1):40.","journal-title":"J Hematol Oncol"},{"key":"1768_CR36","doi-asserted-by":"publisher","first-page":"102986","DOI":"10.1016\/j.esmoop.2024.102986","volume":"9","author":"JD Bradley","year":"2024","unstructured":"Bradley JD, Sugawara S, Lee KHH, Ostoros G, Demirkazik A, Zemanova M, et al. LBA1 durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2. ESMO Open. 2024;9:102986.","journal-title":"ESMO Open"},{"key":"1768_CR37","first-page":"100808","volume":"24","author":"S Peters","year":"2024","unstructured":"Peters S, Tan DSW, Gerber DE, Urbanic J, Ramalingam SS, Yu J, et al. 65O checkmate 73L: phase III study comparing nivolumab (N)\u2009+\u2009concurrent chemoradiotherapy (CCRT) followed by N\u2009+\u2009ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC. IOTECH. 2024;24:100808.","journal-title":"IOTECH"},{"key":"1768_CR38","doi-asserted-by":"publisher","first-page":"S991","DOI":"10.1016\/j.annonc.2022.07.1097","volume":"33","author":"M Ozguroglu","year":"2022","unstructured":"Ozguroglu M, Levy B, Horinouchi H, Yu J, Grainger E, Phuong P, et al. 971TiP phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8). Ann Oncol. 2022;33:S991.","journal-title":"Ann Oncol"},{"issue":"29","key":"1768_CR39","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1080\/14796694.2024.2354160","volume":"20","author":"F Barlesi","year":"2024","unstructured":"Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, et al. PACIFIC-9: phase III trial of durvalumab\u2009+\u2009oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncol. 2024;20(29):2137\u201347.","journal-title":"Future Oncol"},{"issue":"16_suppl","key":"1768_CR40","doi-asserted-by":"publisher","first-page":"8046","DOI":"10.1200\/JCO.2024.42.16_suppl.8046","volume":"42","author":"C Aggarwal","year":"2024","unstructured":"Aggarwal C, Martinez-Marti A, Majem M, Barlesi F, Carcereny E, Chu QS, et al. Updated results from COAST, a phase 2 study of durvalumab (D)\u2009\u00b1\u2009oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). J Clin Oncol. 2024;42(16_suppl):8046\u20138046.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1768_CR41","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.jtho.2023.06.002","volume":"18","author":"C Dickhoff","year":"2023","unstructured":"Dickhoff C, Heineman DJ, Bahce I, Senan S. Unresectable stage III NSCLC can be reevaluated for resectability after initial treatment. J Thorac Oncol. 2023;18(9):1124\u20138.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"1768_CR42","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.cllc.2024.06.007","volume":"25","author":"M Reck","year":"2024","unstructured":"Reck M, Nadal E, Girard N, Filippi AR, Martin LW, Gay CM, et al. MDT-BRIDGE: neoadjuvant durvalumab plus chemotherapy followed by either surgery and adjuvant durvalumab or chemoradiotherapy and consolidation durvalumab in resectable or borderline-resectable stage IIB-IIIB NSCLC. Clin Lung Cancer. 2024;25(6):587\u201393. e3.","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"1768_CR43","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","volume":"42","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Pan Y, Yang X, Zhao Y, Han G, Pang Q, et al. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial. Cancer Cell. 2024;42(7):1258\u201367. e2.","journal-title":"Cancer Cell"},{"key":"1768_CR44","doi-asserted-by":"publisher","first-page":"107326","DOI":"10.1016\/j.lungcan.2023.107326","volume":"184","author":"J Zheng","year":"2023","unstructured":"Zheng J, Li Y, Jin C, Ruan K, Sun K, Chen H, et al. Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer. Lung Cancer. 2023;184:107326.","journal-title":"Lung Cancer"},{"issue":"6","key":"1768_CR45","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jtcvs.2022.03.034","volume":"164","author":"K Furrer","year":"2022","unstructured":"Furrer K, Weder W, Eboulet EI, Betticher D, Pless M, Stupp R, et al. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. J Thorac Cardiovasc Surg. 2022;164(6):1587\u2013602. e5.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1768_CR46","doi-asserted-by":"publisher","first-page":"1289207","DOI":"10.3389\/fimmu.2023.1289207","volume":"14","author":"S Guan","year":"2023","unstructured":"Guan S, Zhang S, Ren K, Li X, Li X, Zhao L. Induction chemoimmunotherapy may improve outcomes of chemoradiotherapy in patients with unresectable stage III NSCLC. Front Immunol. 2023;14:1289207.","journal-title":"Front Immunol"},{"issue":"1","key":"1768_CR47","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41467-025-57184-z","volume":"16","author":"C Yi","year":"2025","unstructured":"Yi C, Bian D, Wang J, Hu S, Sun L, Yan Y, et al. Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial. Nat Commun. 2025;16(1):1932.","journal-title":"Nat Commun"},{"issue":"6","key":"1768_CR48","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-24-3476","volume":"31","author":"MM Smeenk","year":"2025","unstructured":"Smeenk MM, van Diessen JNA, Boellaard TN, Hartemink KJ, de Vries JF, van der Noort V, et al. Tremelimumab plus durvalumab prior to chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer: the induction trial. Clin Cancer Res. 2025;31(6):1037\u201346.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01768-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01768-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01768-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:02:11Z","timestamp":1765422131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-025-01768-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1768"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01768-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and amendments were reviewed and approved by the ethics committees at each centre. All the participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y-LW has received research grants (paid to the institution) from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Jiangsu Hengrui, and Roche; and reports a speaker, consultant or advisor role for AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Pfizer, Roche, and Sanofi. TC has participated on an advisory board for AstraZeneca; has undertaken a coordinating PI role for Astellas Pharma, AstraZeneca, Merck KgaA, Merck Sharp & Dohme, Bristol Myers Squibb, Daiichi Sankyo, Johnson and Johnson, Amgen, Lilly, Stemline, Sandoz, Roche, BioNTech SE, Boehringer Ingelheim, Regeneron, Immuntep, AbbVie, and Duality; and reports an invited speaker role for Nobel, Astellas Pharma, Takeda, Daiichi Sankyo, Bristol Myers Squibb, Abdi Ibrahim, Johnson and Johnson, Deva, and Amgen. YP reports a principal investigator role for AstraZeneca; and speaker fees from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Pfizer, and Roche. MK reports an advisory role, participation on an advisory board, PI, coordinating PI, and local PI roles, speaker, consultant, or advisory fees, and an invited speaker role for Roche, Merck Sharp & Dohme, Bristol Myers Squibb, AstraZeneca, and Takeda. MANS reports participation on an advisory board and an invited speaker role for Roche, AstraZeneca, Pfizer, Novartis, Astellas, Bristol Myers Squibb, Merck Sharp & Dohme, Lilly, Gilead, Takeda, and Janssen. Y-CK reports research grants from AstraZeneca; speaker, consultant or advisor fees from AstraZeneca, Takeda, and Yuhan; and is a steering committee member for Yuhan. YY, RM and BZ are employees of and may own stock\/stock options with AstraZeneca. The remaining authors have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}